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The female reproductive system (FRS) has a great capacity for regeneration. The existence of somatic stem cells
(SSC) that are likely to reside in distinct tissue compartments of the FRS is anticipated. Normal SSC are capable of
regenerating themselves, produce a progeny of cells that differentiate and maintain tissue architecture and
functional characteristics, and respond to homeostatic controls. Among those SSC of the FRS that have been
identified are: a) undifferentiated cells capable of differentiating into thecal cells and synthesizing hormones upon
transplantation, b) ovarian surface epithelium stem cells, mitotically responsive to ovulation, c) uterine endometrial
and myometrial cells, as clonogenic epithelial and stromal cells, and d) epithelial and mesenchymal cells with
self-renewal capacity and multipotential from cervical tissues. Importantly, these cells are believed to significantly
contribute to the development of different pathologies and tumors of the FRS.
It is now widely accepted that cancer stem cells (CSC) are at the origin of many tumors. They are capable of
regenerating themselves, produce a progeny that will differentiate aberrantly and do not respond adequately to
homeostatic controls. Several cell surface antigens such as CD44, CD117, CD133 and MYD88 have been used to
isolate ovarian cancer stem cells. Clonogenic epithelial and stromal endometrial and myometrial cells have been
found in normal and cancer tissues, as side population, label-retaining cells, and CD146/PDGF-R beta-positive cells
with stem-like features. In summary, here we describe a number of studies supporting the existence of somatic
stem cells in the normal tissues and cancer stem cells in tumors of the human female reproductive system.
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Somatic stem cells (SSC) share three common features;
i) generate identical cells retaining this capacity over long
periods (referred as long-term self-renewal), ii) produce a
progeny that differentiates into mature cells exhibiting
specialized functions, iii) respond to homeostatic controls
regulating decision to self renew or produce differentiating
progenitors. Contrary, cancer stem cells (CSC) although
self-renew, generate a progeny that differentiates albeit
aberrantly, and fail to properly respond to homeostatic* Correspondence: carranca@biomedicas.unam.mx
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reproduction in any medium, provided the orcontrols. CSCs can be defined experimentally by their
ability to recapitulate a continuously growing tumor.
Existence of stem cells within distinct tissue compart-
ments of the FRS is well documented, as the contribu-
tion of CSCs in the development of different neoplasias
(Figure 1). Experimental strategies for isolation and
identification of cancer stem cells, as well as major
tumor types originating within the FRS together with
genetic mutations and clinical treatments are shown
(Table 1). We present evidences based in an extensive
description of markers expression and functional assays
(Table 2) supporting existence of both normal and
cancer stem cells in the human FRS, as well as their role
in the normal physiology and gynecological pathologies.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Summary of current evidences supporting the existence of stem cells in the female reproductive system. The existence of
stem/progenitor cells is indicated in primary functional parts of the reproductive system, including ovary, uterus and cervix. Abbreviations:
CD = Cluster of differentiation, MSC =Mesenchymal stem cell, SP = Side population.
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Functional assays
Isolation of SC from the theca and ovarian surface
epithelium (OSE) has been possible recently. Thecal
stem cells were obtained after dissociating newborn mice
ovaries and growing them in serum-free germline stem
cell media [1]. Nonadherent anchorage-independent
spheres exhibited appropriate gene profiles, compatible
with theca cells that differentiate into early precursors and
steroidogenic cells in a stepwise manner after treatment
with serum, luteinizing hormone, and paracrine factors
from granulosa cells, and later secreted androstenedione.
At each step these cells displayed appropriate gene expres-
sion profiles and morphological features and achieved a
mature morphology when coculture with isolated
granulosa cells. In addition, they colonized exclusively the
ovarian interstitium and the theca layer of follicles when
transplanted into ovaries of recipient animals [1].
A population of label-retaining cells (LRC) residing in
the coelomic epithelium and exhibiting quiescence,
in vivo functional response to hormonal stimulus, and
enhanced in vitro colony formation have been identified
as candidate for somatic stem/progenitor cells of the
mouse ovary [2].Existence of ovarian CSCs is supported by identifica-
tion and isolation of tumorigenic sphere-forming clones
from ascites of patients with epithelial ovarian cancer
[3]. Immunohistological evidence suggested differenti-
ation along epithelial, granulosa, and germ cell lineages.
Independent clones showed an ability to form spheroids
and multicellular colonies in soft agar correlating with
tumorigenicity. Xenografted tumors could be serially
passaged through at least three generations in vivo,
indicating their capacity to self-renew.Markers
Ovarian CSCs were found to form tumors faster and
with less inoculums, when injected into the dorsal fat
pad of nude mice. Müllerian-inhibiting substance was
able to reduce the growth of these cells in vitro. Surface
proteins such as c-Kit, CD44 and CD133 have been
associated with ovarian cancer cells with stem-like
phenotype [4-8]. Expression of CD133-1 and CD133-2,
which were detected in ovarian carcinomas, was also
observed in normal ovaries. CD133+ ovarian tumor cells
were characterized by a higher proliferative potential and
clonogenic efficiency than negative cells [7]. CD133- cells
Table 1 Major tumor types in gynaecological cancer; genetic mutations and clinical treatments
Organ Common tumor type Mutations Treatment
Ovary
[12]
Ovarian epithelial carcinoma Loss of heterozygosity of PTEN, P53, K-ras,
HNPCC mutations. BRCA1 and 2 inactivating
mutation. ABCG2 overexpression, β-Catenin
expression
Early stage: Ovarian surgery. Rarely detected at an
early stage, because there is no definitive marker,
but a combined immunoassay with six markers
[leptin, prolactin, osteopontin, insulin-like growth
factor II, macrophage inhibitory factor and CA 125].
In addition, the use of kallikrein or protease M and
osteopontin are helpful
Endometrioid, Serous, Clear cells,
Transitional, Mucinous and
Undifferentiated carcinoma




Novel Agents: Antiangiogenic agents, Tyrosine




Endometrial carcinoma type I
[estrogen] and II [no estrogen
related], Adenocarcinoma
Sarcoma
PTEN inactivation, K-ras, P53 and P16 mutations,
Microsatellite instability, HER-2/neu
overexpression
Early stage: Hysterectomy, bilateral
salpingoophorectomy and pelvic and periaortic
lymph node dissection. Hormonal therapy with
Progesterone in the form of an intrauterine device
[IUD], cyclic progesterone or Megace
Myometrium cancer Advanced and/or recurrent stage: Chemotherapy




Adjuvant radiation. Hormonal Therapy with
medroxyprogesterone
Endometrial cancer in advanced
stage with myometrial invasion
Novel Agents: Ephotilones, Mammalian target of
Rapamycin [mTOR] Inhibitors, Angiogenesis




Cervical carcinoma K-ras mutations Carbonic anhydrase Early stage: Laparotomic lymphadenectomy
Radical trachelectomy, Hysterectomy. Adjuvant and





IX [CAIX], CAXII, hypoxia-inducible factor 1α, and
VEGF upregulation
Advanced and/or recurrent stage: Adjuvant
Chemotherapy
Deregulated expression of E6 and E7 viral
oncogenes
Novel Agents:Genome wide expression arrays,
MiRNAs, Hyperbaric oxygenation for tumour
sensitisation to radiotherapy.
The early or advanced stage depends on the extent of local spread [shown by the tumour stage and tumour size], nodal status and histological subtype. The
grading is based on the WHO International Histological Classification of Tumours and Classification of Diseases for Oncology.
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ovarian cancer patients were shown to be tumorigenic [6].
CD133+ cells derived from ovarian tumors were capable
of self-renewal and were associated with increased tumor
aggression in xenografts. Furthermore, they identified that
epigenetic deregulation of CD133 may be associated with
transformation [6]. Using in vivo serial transplantations,
contribution to establishment of tumor vasculature of
these cells was demonstrated [9]. Other studies showed
that CD133+ ALDH+ coexpressing cells had greater
tumor initiating capacity in ovarian cancer cell line and
primary human ovarian tumors [10,11]. Moreover, CD133,
CD117, CD44 and CD24 markers could be used as CSC
markers alone or in combination to identify distinct FRS
CSC population. However, it is relevant to establish if the
markers expressed are functionally related to each other,
and their clinical implications.In the other hand, it has been previously reported that
several markers are also expressed in normal stem cells
or even in other tissues, which implies the need of fur-
ther studies to develop therapeutic targets and delimitate
their activity as possible clinical treatments.
A study of ovarian serous adenocarcinomas identified a
population of tumorigenic self-renewing ovarian CSCs that
can grow as sphere-forming clusters under nonadherent
conditions [4]. When xenografted, as few as 100 spheroid-
dissociated cells allowed full recapitulation of the ori-
ginal tumor, whereas >1 × 105 unselected cells remained
nontumorigenic. Enhanced chemoresistance to cisplatin
or paclitaxel and up regulation of stem cell markers
(including Bmi-1, Stem Cell Factor, Notch-1, Nanog,
Nestin, ABCG2, and Oct-4) were further established.
Immunostaining showed significant up regulation of
CD44 and stem cell factor receptor c-Kit [4].
Table 2 Markers of cancer stem cells of the female
reproductive system
Tumor type Marker References
Ovarian cancer SP+ Szoket, 2006 [2]
Clonogenic cells Bapat, 2005 [3]
CD44+, CD117+ Zhang, 2008 [4]




CD44+, MYD88+ Alvero, 2009 [8]
Uterine cancer Clonogenic cells Hubbard, 2009 [24]
SP+ Friel, 2008 [25]
Kato, 2010 [26]
Cervical cancer p63 y CK17 eliminated
Nanog, Musashi-1, Nucleostemin Ye, 2008 [30]
Spheres, ALDH1, CD44 Li, 2011 [33]
Spheres-CD49f Li, 2011 [33]
Spheres López, 2012 [32]
ALDH1 Gu, 2011 [34]
CD44
Abbreviations: CD, Cluster of differentiation, LRC, Label-retaining cell, SP, Side
population, PDGF-Rβ, PDGF-receptor β, ALDH, Aldehyde dehydrogenase, MSC,
mesenchymal stem cell.
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expressed a complex pattern of CD44 splice variants.
CD44S and CD44-9v were common features of epithelial
ovarian cancer cells, although no association between
CD44 variants expression and clinical stage, residual
disease, age, histology, grade, or survival was observed,
suggesting other factors may be more important in
determining clinical behavior [12].
CD44+, MYD88+ cells from ascites and solid tumors
have been characterized by constitutive nuclear factor
kappa beta (NF-κβ) activity, cytokine and chemokine pro-
duction, high capacity for repair, chemoresistance to con-
ventional chemotherapies, resistance to TNF-α-mediated
apoptosis, capacity to form spheroids in suspension, and
the ability to recapitulate in vivo the original tumor [8].
The same research group identified bipotent CD44+
CD34− cells in ovarian cancer and demonstrated that,
in addition to being capable of tumor regeneration,
these cells also contribute to tumor vascularization by
a mechanism that involves inhibitor of kappa-kinase
beta (IκK-β). Aldehyde dehydrogenase1 (ALDH1) did
not appear to be co-expressed with CD44, CD117 and
CD133. Furthermore, reduced ALDH1 expression was
associated with malignant transformation in ovarian
cancer.Normal uterine and cancer stem cells
Normal endometrial stem cells
Multiple endometrial stem cells (ESC) including epithelial,
mesenchymal and endothelial cells may contribute to
rapid endometrial regeneration following menstruation.
Markers
Endometrial mesenchymal stem cells (MSCs) are pro-
spectively isolated as CD146+, PDGF-Rβ+ (platelet-derived
growth factor receptor beta) cells and are found in both
basalis and functionalis as perivascular cells. Endometrial
epithelial progenitor cells (EPCs) have been detected as SP
cells, expressing several endothelial cell markers and
differentiating into epithelial, stromal and endothelial cells.
Investigating ESC biology is crucial to understanding
normal endometrial physiology and determining their
roles in endometrial proliferative diseases [13-15].
Functional assays
Human epithelial and stromal cells from endometrial
tissues showed approximately 0.15% of epithelial (0.01%
forming large CFUs and 0.14% forming small CFUs) and
1.25% of the stromal cell populations are clonogenic
(0.02% large CFUs and 1.23% small CFUs) [13-15]. Large
epithelial colonies show reactivity for alpha(6)-integrin
(CD49f). All colonies contain fibroblasts expressing stro-
mal markers, and the highest clonogenicity of stromal
cells is observed in the proliferative stage, whereas peak
clonogenicity of epithelial cells is found in the secretory
stage. Interestingly, clonogenicity within the stromal and
epithelial cell fractions do not differ between actively
and inactively menstruating women, suggesting that
ovarian-derived steroid hormones do not maintain the
clonogenic potential of uterine epithelial and stromal
tissues [13].
Subsequent studies on stromal CFUs indicate that in-
dividual large CFUs had substantial self-renewal activity
in vitro, undergoing serial subcloning 2.9 and 3.3 times,
respectively, whereas small CFUs serially cloned 0.5 only
one time [16]. On the other hand, large epithelial and
stromal CFU stem cell-like progenitors have high prolif-
erative potential and undergo 34 and 30 population dou-
blings before senescence or transformation [16].
Single large stromal CFUs derived from freshly isolated
endometrial tissue underwent multilineage differentiation
into four mesodermal lineages when cultured under
appropriate conditions including smooth muscle cells,
adipocytes, chondrocytes and osteoblasts [16]. Stromal
clones expressed MSC markers ITGB1 (CD29), CD44,
NT5E (CD73), THY1 (CD90), ENG (CD105), PDGF-Rβ
(CD140B), MCAM (CD146) but not endothelial or
hemopoietic markers. Adult human endometrium con-
tains rare epithelial progenitors and MSCs, likely respon-
sible for its immense regenerative capacity, which may
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and EC [16,17]. According to this, endometrial cell clones
derived from in vitro cultured and purified stromal cells
display characteristic stem cell features including clonality,
long-term culturing properties, multilineage differenti-
ation potential, expression of CD146, CD105, CD90,
CD73, Msi-1, Notch1, and Sox2, and absence of CD34
and CD14 expression [18]. This finding is supported by
more extensive differentiation studies in which rare (1.5%)
CD146+, PDGF-Rβ+ stromal cells could be induced to
differentiate into osteocytes, chondrocytes, myocytes, and
adipocytes [19,20]. CD146+, PDGF-Rβ+ cells expressed
typical MSC surface markers, CD29, CD44, CD73, CD90
and CD105 and were negative for hemopoietic and
endothelial markers. These cells were located peri-
vascularly in both functionalis and basalis layers of
human endometrium.
SP cells have been identified in fresh endometrium
isolates and short-term cultures of human endometrial
cells, with high variability among subjects, although
higher numbers were found in the menstrual and prolif-
erative stages, with around 0.0–5.1% of cells in normal
human endometrium constituting this fraction [16].
Cervello et al. characterized the SP corresponding to
the stromal and epithelial compartments using endo-
metrial SP (ESP) gene signatures, immunophenotyping
and characteristic telomerase pattern. They demon-
strated functional capability of ESP to develop human
endometrium after subcutaneous injection in non-obese
diabetes/severe combined immunodeficiency (NOD/
SCID) mice [17].
A medium specific for endothelial cell culture enabled
SP cells to proliferate and differentiate into various types
of endometrial cells including glandular epithelial, stromal
and endothelial cells in vitro, whereas in the same
medium, endometrial main population (MP) cells differ-
entiated into only stromal cells. Furthermore, SP cells,
but not MP cells, reconstituted organized endometrial
tissue with well-delineated glandular structures when
transplanted under the kidney capsule of severely im-
munodeficient mice. Notably, SP cells generated endo-
thelial cells that migrated into the mouse kidney
parenchyma and formed mature blood vessels [21].
Together these data indicate that SP cells both in vitro
and in vivo produce endometrial epithelial and stromal
cells; however, the hierarchical relationship between SP
cells, clonogenic cells, CD146+, PDGF-Rβ+ cells, and
tissue-reconstituting cells remains to be elucidated.
Normal myometrial stem cells
Functional assays
SP cells were isolated from the myometrium (myoSP) of
patients undergoing hysterectomy [22]. myoSP resided
in quiescent cells, and myometrial cell markers wereunder expressed or missing. These cells could proliferate
and eventually differentiate into mature myometrial cells
in vitro only under low oxygen concentration. Although
the main population expressed myo (myoMP) and
displayed mature myometrial phenotypes before and
after in vitro cultivation, only myoSP, not myoMP, gener-
ated functional human myometrial tissues efficiently
when transplanted into the uteri of severely immunode-
ficient mice. Finally, myoSP were multipotent and made
to differentiate into osteocytes and adipocytes in vitro
under the appropriate differentiation-inducing condi-
tions. Thus, myoSP exhibited phenotypic and functional
characteristics of myometrial stem cells. Study of myoSP
will improve the understanding of myometrial physi-
ology and the pathogenesis of myometrium-derived
diseases such as leiomyoma. myoSP may also represent a
novel source of biological material that could be used in
the reconstruction of not only the human uterus but
also other organs as well [22].
Markers
Human and murine myometrial progenitors have been
characterized by surface markers and found CD31+,
CD34+, CD44+, CD117+, Stro-1+ and Sca-1+. These cells
can differentiate in vitro into a number of mesodermal
(smooth and skeletal muscle, osteoblasts and adipocytes)
as well as epidermal lineages (all neural lineages). Im-
portantly, when injected into animal models of muscular
disease, this population can regenerate new muscle fi-
bers and promote functional muscular recovery. More-
over, these cells can regenerate the uterine lining after
wound healing, reconstructing the uterine muscular
architecture and forming new vessels both in vitro and
in vivo. These results strongly suggest that a resident
population of myometrial cells can functionally behave
like myometrial stem cells.
Endometrial cancer stem cells
Functional assays
In a study of a uterine carcinosarcoma-derived cell line,
colony-initiating cells grew for >50 serial passages and
were composed of cells with columnar, small epithelial,
moderately sized or large epithelial like, malignant
tumor giant and spindle-shaped morphologies, similar to
those found in the original cell line. These highly prolif-
erative clonal cells expressed immunohistochemical and
molecular markers consistent with their parental tissue
and recapitulated the tumor phenotype in vitro [23].
Isolated endometrial carcinoma cells, when transplanted
under the kidney capsule of immunocompromised mice in
serial dilution 2 × 106 −1 × 104 cells, generated tumors in 8/
9 samples with morphologies similar to the parent tumors.
These tumors recapitulated cytokeratin, vimentin, estrogen
receptor alpha, and progesterone receptor expression of the
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also expressed the self-renewal genes BMI-1, Nanog, and
Sox-2. Isolated cells from primary tumors were serially
transplanted three to five times in NOD/SCID mice,
showing self-renewal in vivo [24,25].
A study has examined several cell lines and four high-
grade EC samples for the presence of SP cells [25]. In
the AN3CA and Ishikawa, but not the SKUT-2 and
HEC-1 cell lines, rare SP cells were detected (3.4%)
demonstrating CSCs traits, including slow growth, as
evidenced by a higher percentage of cells in G1, and
their capacity to initiate tumors in NOD/SCID mice
when injected subcutaneously [25]. Furthermore, the
HEC-1-A SP population was showed to be clonogenic
and self-renewed in the serial cloning assay and initiated
larger tumors than the non-SP population. Interestingly,
HEC-1-A SP cells produced tumors comprising epithe-
lial tumor cells and vimentin-, α-SMA- and collagen III-
expressing stromal cells, indicating that an epithelial to
mesenchymal transition had occurred during cancer
progression of the SP cell-initiated tumors in vivo [26].
In a study examining 113 patient samples covering
the full spectrum of EC, primary tumor samples exhibited
a variable degree of immunoreactivity for CD133/1
(1.3 − 62.6%). Dissociated bulky tumors formed sphere-like
structures, maintained CD133 expression and could be
propagated for up to 12 weeks. CD133+ cells purified
from endometrioid adenocarcinomas were resistant
to cisplatin- and paclitaxel-induced cytotoxicity and
expressed a peculiar gene signature consisting of high
levels of matrix metalloproteases, interleukin-8, CD44,
and CXCR4. When serially transplanted into NOD/
SCID mice, CD133+ cells were capable of initiating
tumor formation and recovering the phenotype of the
original tumor [27].
Markers
ALDH1 was detected in a small population of endomet-
rial tumor cells that were less mature. ALDH1-positive
cells were more tumorigenic, resistant to anticancer
agents, and more invasive than ALDH1 negative or low
cells. Clinically, high-level of ALDH1 was correlated
with lymphatic invasion, recurrence, and poor prognosis
of patients. ALDH1 is a candidate CSCs marker for
uterine endometrioid adenocarcinoma [28]. Msi-1 was
immunolocalized to single epithelial cells and small
clusters of stromal cells in endometrial, endometriotic
and endometrial carcinoma tissue specimens. Msi-1+
cells were mainly found in the basalis in the proliferative
stage of the menstrual cycle, suggesting their possible
stem/progenitor cell function. Stromal Msi-1+ cells
were not found in a perivascular location, although
some were in a periglandular region, a similar location
to some stromal LRCs in mouse endometrium [15]. Alarge proportion of endometriotic glands expressed Msi-1+.
Immunofluorescence microscopy revealed colocalization of
Msi-1 with its molecular target Notch-1 and telomerase.
In endometrium, MSCA-1, a bone marrow-derived
MSC surface marker identified as tissue nonspecific
alkaline phosphatase (TNAP), is expressed at inter-
mediate levels on CD146+ cells and at high levels in
the luminal space of glandular epithelia. In conclusion,
human endometrium also harbors a rare population
with MSC and fibroblast properties that can be par-
tially purified as a CD146+, PDGF-Rβ+ population.
A higher proportion of the rare these cells differen-
tiate compared to unfractionated fibroblasts, and in-
dividual CFU are truly multipotent as their progeny
differentiate into multiple mesodermal lineages. This
suggests that a hierarchy exists in the MSC-fibroblast
lineage. Clearly this needs further molecular, genetic and
in vivo characterization.
Cervical cancer stem cells
Markers
Although limited, evidence supporting the existence of
stem-like cells in cervical tumors is convincing. They
have been identified in the uterine cervical epithelium as
P63 and CK17-positive cells in cervical intraepithelial
neoplasia (CIN) grades I - III. In all cases, P63 was found
strongly expressed in the basal layer of the lesions. The
distribution pattern and marker profile of reserve cells
along the adult human endocervical canal was studied
and two subpopulations of reserve cells were found: a
CK17-positive subpopulation in the lower part of the
cervical canal with a progenitor cell function for the
squamous and columnar epitheliums, and a subpopula-
tion of CK17-negative reserve cells with a progenitor cell
function only for columnar cells [29].
Ye et al. examined the expression of Nanog, Nucleostemin
(NS) and Musashi1 (Msi1) in cervical epithelial lesions
and in cervical carcinomas and assessed their associ-
ation with several prognostic variables. There was an
association between expression of these three proteins
and the severity of epithelial changes; levels were sig-
nificantly higher in cervical squamous cell carcinoma
(CSCC) compared with CIN, and with normal cervical
epithelia. High expression of these proteins may be in-
volved in carcinogenesis of the cervix and progression
to cervical carcinoma. However, there was no positive
correlation between expression levels and clinical patho-
logical prognostic factors [30]. The expression of other
markers as PSCA, PIWIL1 and TBX2 was evaluated in
CSCC and normal adjacent cervix. In general, expres-
sion rates were higher in cancer and associated with
invasion. Also, expression of SOX2 was evaluated in
normal and pathologic cervical tissues, and in cervical
cancer tumorspheres and differentiated cells. While80%
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with only 25% of normal cervix, CSCC grades II and III
showed relatively higher intensity of SOX2 staining
compared with that of squamous carcinoma I. Also,
SOX2 was strongly expressed in primary tumorspheres
derived from fresh cervical cancer tissues, but was never
or seldom detected in differentiated cells. Additionally,
it was found that exogenous SOX2 could promote both
cell proliferation and growth, and enhanced tumor forma-
tion in nude mouse. Contrary, Cantz et al. were unable to
detect significant levels of OCT4 mRNA or protein in
HeLa cells, and found that OCT4 promoter region is
highly methylated in these cells [31]. These authors
argue that reports of OCT4 expression in this and
other cancer cell lines could in reality be attributed to
the expression of six OCT4 pseudogenes or to misinter-
pretation of background signals. Expression of ALDH1 in
cervical carcinoma was evaluated and it was found that
23/89 invasive squamous carcinomas and 4/20 adenocar-
cinomas exhibited immunoreactivity to ALDH1and that
cervical carcinoma cells had low CD133 expression, simi-
lar to found by Lopez et al. [32].
Functional assays
Epithelial-mesenchymal transition (EMT) can endow
cells with stem cell-like characteristics. Li et al. induced
EMT in breast cancer MCF7 and CC HeLa cells with
expression of Twist, a key transcriptional factor for this
transition. They also found that expression of ALDH1
and CD44 were significantly elevated in Twist-over ex-
pressing cells, and that β-catenin and Akt pathways were
activated. This study suggests that this activation is crit-
ical for the maintenance of EMT, and that targeting β-
catenin and Akt pathways can suppress EMT-associated
stem cell-like properties [33].
A CSC population from primary carcinoma of the
cervix uteri was identified. Eight of 19 tumor-derived
cultures encompassed CSC capable of self-renewal and
extensive proliferation as clonal non-adherent spherical
clusters. Spheroids were identified as CD44+ CK17+, and
while only 48% of sphere-forming cells were inhibited by
doxorubicin, 78% of non-sphere forming cells were
inhibited. Xenoengraftment of 1 × 105 dissociated spheroid
cells allowed full recapitulation of the original tumor,
whereas the same amount of non-adherent spheroid
selection remained non-tumorigenic. They found that
spheroid cells were CD34 negative, as shown by Lopez
and colleagues [32].
Gu et al. isolated Sphere-forming cells (SFC) from
HeLa and SiHa cell lines and found they were tumori-
genic with 1 × 104 cells. They further demonstrated that
HeLa-SFC expressed a higher level of the HPV oncogene
E6, compared with that of parental HeLa cells. Silencing
of E6 inhibited HeLa-SFC sphere formation and cellgrowth. They found all three isoforms of the transform-
ation growth factor-β (TGF-β) were significantly down
regulated while the leukemia-inhibitory factor remained
unchanged. This suggests that E6 silencing exerts a
specific effect on the expression of TGF-β [34].
Lopez et al. characterized a self-renewing subpopula-
tion of CSC among four cancer-derived cell lines, HeLa,
SiHa, Ca Ski, and C-4 I, and found that these express
the CSC markers characteristic of the FRS including
CD44, ITGB1 (CD29), PSCA, NT5E (CD73), ENG
(CD105), MYC (c-Myc), PCGF4 (BMI-1), and ABCG2.
Other epithelial CSC markers found included ITGB6,
ALCAM (CD166), and MET (c-Met) [32]. Interestingly,
components of the double-strand break DNA repair ma-
chinery and genes involved in the metabolism of reactive
oxygen species were also up-regulated and indeed, dose-
dependent radiation assays indicated that CSC-enriched
populations exhibit increased resistance to ionizing radi-
ation. CSC enriched as spheroids highly expressed
CD49f and could generate reproducible tumor pheno-
types in immunodeficient nu-nu mice and could be
propagated serially. Injection of 1 × 103 dissociated cells
from spheroids induced tumors in the majority of animals,
as opposed to injection of 1 × 105 cells grown as monolayer.
In addition, EMT transition-associated markers were found
highly expressed in spheroid cells.
Together these results suggest that cervix CSCs
participate in carcinogenesis of this tissue and these
cells may be potential therapeutic target molecules for
cervical cancers; however, this is a new area under investi-
gation and many questions remain to be answered.
Conclusions
Stem cells play a pivotal role in the physiology of the
normal FRS and are likely to be involved in the response
of these tissues to injury and disease. Many studies have
provided strong evidence for the existence of SSCs in
the human endometrium and ovary. However, stem cell
biology of the human FRS is still in its infancy, and
although surface markers for prospective isolation of hu-
man endometrial colony-forming cells have been identi-
fied, there remains a need to identify definitive markers
for more selective isolation and enrichment of stem cells
from all tissues and organs of the FRS. Complete
characterization of these stem/progenitor cells will im-
prove our understanding of the mechanisms supporting
physiological regeneration of the FRS. Additionally,
further investigations are needed to evaluate the clin-
ical correlation between CSC population features, poor
prognosis and progression free survival. Moreover, is
important to establish the functional relationship be-
tween markers, since it is known that some are also
widely expressed and shared by normal tissues and
stem cells. Therapeutic approaches that directly target
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specific effects need to be considered. Animal transgenic
and xenografts model systems also need to be implemented
in order to examine the hallmark characteristics of FRS
stem cells and shared by all stem cells, i.e., potential for
self-renewal, lineage differentiation and homeostatic
control. Such studies will enhance our understanding
of ovarian, uterine and cervix cancer and may prove
helpful in the treatment of these conditions.
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